1.24
-0.06(-4.62%)
Currency In USD
| Previous Close | 1.3 |
| Open | 1.29 |
| Day High | 1.29 |
| Day Low | 1.23 |
| 52-Week High | 3.46 |
| 52-Week Low | 1.09 |
| Volume | 527,785 |
| Average Volume | 1.25M |
| Market Cap | 76.2M |
| PE | -0.43 |
| EPS | -2.86 |
| Moving Average 50 Days | 1.25 |
| Moving Average 200 Days | 1.45 |
| Change | -0.06 |
If you invested $1000 in Pliant Therapeutics, Inc. (PLRX) since IPO date, it would be worth $58.22 as of February 21, 2026 at a share price of $1.24. Whereas If you bought $1000 worth of Pliant Therapeutics, Inc. (PLRX) shares 5 years ago, it would be worth $35.47 as of February 21, 2026 at a share price of $1.24.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
GlobeNewswire Inc.
Dec 04, 2025 12:30 PM GMT
One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment of 15 months Company to accelerate development o
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
GlobeNewswire Inc.
Dec 01, 2025 1:30 PM GMT
SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in th
Pliant Therapeutics Provides Update on BEACON-IPF
GlobeNewswire Inc.
Jun 27, 2025 8:05 PM GMT
Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutic